Who Paid My Doc
A Phase 1/2 First-Time-In-Human, Open-Label, Multicenter, Dose Escalat
Research payments
$1,974,278
Through program year 2025, $1,974,278 in research payments was reported against A Phase 1/2 First-Time-In-Human, Open-Label, Multicenter, Dose Escalat, across 430 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,305,138 | 281 |
| 2024 | Research | $586,771 | 140 |
| 2023 | Research | $82,368 | 9 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Minal Barve Dallas, TX Named on 80 payments
- Pamela Munster San Francisco, CA Named on 58 payments
- Alexander Spira Fairfax, VA Named on 58 payments
- Brian Van Tine Shiloh, IL Named on 46 payments
- David Sommerhalder San Antonio, TX Named on 45 payments
- Jason Henry Denver, CO Named on 23 payments
- Ida Micaily Philadelphia, PA Named on 21 payments
- Kari Hacker Raleigh, NC Named on 20 payments
- Benjamin Garmezy Nashville, TN Named on 13 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.